Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy

• DOI: 10.1200/jco.2001.19.9.2449
• Publication Date: 2017-02-24T06:55:01Z
• Authors: Oliver-Louis Chinot; Stephane Honore; Henry Dufour; Maryline Barrie; Dominique Figarel...; Xavier Muracciole; Diane Braguer; Pierre-Marie Martin; François Grisoli
• Keywords: Temozolomide; Lomustine; Anaplastic astrocytoma; Procarbazine; Progression-free survival; Dacarbazine; Tolerability

PURPOSE: Most primary oligodendrogliomas and mixed gliomas (oligoastrocytoma) respond to treatment with procarbazine, lomustine, vincristine (PCV), response rates of approximately 80%. However, limited data on second-line treatments are available in patients recurrent tumors. A novel second-generation alkylating agent, temozolomide, has recently demonstrated efficacy safety glioblastoma multiforme anaplastic astrocytoma. This study describes the effects temozolomide oligodendroglioma (AO) oligoastrocytoma (AOA). PATIENTS AND METHODS: Forty-eight histologically confirmed AO or AOA who had received previous PCV chemotherapy were treated (150 200 mg/m 2 /d for 5 days per 28-day cycle). The end point was objective response. Secondary points included progression-free survival (PFS), time progression, overall (OS), safety, tolerability. RESULTS: Eight (16.7%) experienced a complete response, 13 (27.1%) partial (objective rate, 43.8%), 19 (39.6%) stable disease. For entire group, median PFS 6.7 months OS 10 months. responders, 13.1 16 more than 11. 8 26 Response correlated improved survival. Temozolomide safe well tolerated. Twelve developed grade 1/2 thrombocytopenia three 3/4 thrombocytopenia. CONCLUSION: is effective AOA.